Pharma Deals Review, Vol 2009, No 11 (2009)

Font Size:  Small  Medium  Large

Astellas and Medivation in Pact for Prostate Cancer Drug

Taskin Ahmed

Abstract


Astellas has signed an agreement to co-develop and commercialize MDV3100, a drug for the treatment of prostate cancer developed by Medivation, which is in Phase III clinical trials. The deal could earn Medivation up to US$765 M.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.